5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
Newborn Screening is segmented by Product Type, Test Type, End User (Hospitals, Diagnostic Centers, and Other End Users), and Geography
Fastest Growing Market:
Factors that are responsible for the growth of newborn screening market include growing newborn screening programs, rising incidences of congenital diseases, raising funding from government sectors for newborn screening, and advancements in technologies used in newborn screening.
Newborn screening represents one of the major child health advances of the past century, and there have been many advancements in the technologies used in newborn screening. The rapid pace of developments in the field of newborn screening has been made possible, by technological advances in the ability to detect multiple compounds diagnostic of different inborn errors of metabolism in neonatal dried blood specimens. After the success of newborn screening in phenylketonuria, experts in this area are optimistic that further health benefits may rise in the future. Also, one of the most exciting and powerful advancements in this field is the commercialization of hybrid instruments. The manufacturers are focusing on the high sensitivity, resolution, throughput, and cost-effectiveness to gain a foothold in the market. Hence, many companies have been influenced by emerging technologies, and have adopted many new clinical testing platforms for use.
However, factors, such as the lack of uniformity of newborn screening policies and procedures, across the world, may hinder the market growth.
Newborn screening is a preventive pediatric screening test conducted to diagnose congenital or inborn abnormalities of metabolism, in order to identify the disease. The early detection and appropriate standards of diagnosis and treatment can prevent death, and promote the healthy development of an infant.
|Tandem Mass Spectrometry|
|Enzyme Based Assays|
|By Test Type|
|Dried Blood Spot|
|Critical Congenital Heart Defect (CCHD)|
|By End User|
|Other End Users|
Report scope can be customized per your requirements. Click here.
Dried blood spot tests (DBS) are expected to continue their domination during the forecast period. DBS sampling has been used to screen newborn babies for congenital metabolic diseases, for over 50 years. The advantages of DBS sampling include minimal volume requirements (approximately 30 – 100 µL per spot), ease of sample attainment by finger or heel stick with minimal training required, and ease of transport and sample stability. Autism, lymphomas and leukemia, and many other metabolic conditions can be diagnosed through this test. Dried blood spot analysis offers the advantage of collecting a small sample volume, which is easily transported. Thus, rising diseases in the newborns are boosting the market growth.
To understand key trends, Download Sample Report
Currently, North America dominates the market for newborn screening and is expected to continue its stronghold for a few more years. This is primarily due to the growing prevalence of congenital disorders and enforced testing in all the 50 states of the nation. In the North American region, the United States holds the largest market share. This can be majorly attributed to the increasing incidence rates of the disorders in the newborn and rising demand for advanced systems. The presence of developed healthcare infrastructure is expected to further propel the market in the United States.
To understand geography trends, Download Sample Report.
The newborn screening market is moderately competitive and consists of several major players. In terms of the market share, few of the major players currently dominate the market. A large portion of the market share is held by companies, like Agilent Technologies Inc., Natus Medical Inc., Trivitron Healthcare, Medtronic Inc., Masimo Corp., and Bio-Rad Laboratories Inc., and among others.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Newborn Screening Programs
4.2.2 Rising Incidences of Congenital Diseases
4.2.3 Rising Funding from Government Sectors for Newborn Screening
4.2.4 Advancements in Technologies Used in Newborn Screening
4.3 Market Restraints
4.3.1 Lack of Uniformity of Newborn Screening Policies and Procedures, across the World
4.3.2 False Positive and False Negative Results
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Technology
5.1.1 Tandem Mass Spectrometry
5.1.2 Pulse Oximetry
5.1.3 Enzyme Based Assays
5.1.4 DNA Assays
5.2 By Test Type
5.2.1 Dried Blood Spot
5.2.2 Hearing Screening
5.2.3 Critical Congenital Heart Defect (CCHD)
5.3 By End User
5.3.2 Diagnostic Centers
5.3.3 Other End Users
5.4.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.4.4 Middle East & Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East & Africa
5.4.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AB Sciex
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 GE Healthcare
6.1.4 Masimo Corporation
6.1.5 Medtronic Inc.
6.1.6 Natus Medical Incorporated
6.1.7 PerkinElmer Inc.
6.1.8 Trivitron Healthcare
6.1.9 ZenTech SA
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments